Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Hematol Oncol Clin North Am. 2021 Jan 26;35(2):159–176. doi: 10.1016/j.hoc.2020.12.001

Figure 1.

Figure 1.

Major clinical investigators responsible for early diagnostic and therapeutic advances in myeloproliferative neoplasms. Louis Henri Vaquez was the first to describe polycythemia vera, which was later expanded by William Osler. William Dameshek described pathologic links and coined the term “myeloproliferative disorders.” Philip Fialkow identified myeloproliferative neoplasms as a stem cell disease and Louis Wasserman formed the Polycythemia Vera Study Group, the first dedicated organization to study therapies in myeloproliferative neoplasms.